Press Releases
  Date Title View
ROCKVILLE, Md., March 06, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that it has entered into a settlement agreement with Zydus Pharmaceutical (USA), Inc. and Cadila Heal...
Posted: Mar 6, 2017
Fourth quarter 2016 net product sales were $61.1 million, a 43% increase over 2015.Fourth quarter operating income was $16.3 million, a 107% increase over 2015.Fourth quarter diluted earnings per share were $0.26, an 86% increase over 2015.Full year 2016 net product sales were $210.1 million, a 46% increase over 2015.Full year 2016 operating income...
Posted: Feb 28, 2017
ROCKVILLE, Md., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the company and host invest...
Posted: Feb 27, 2017
ROCKVILLE, Md., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial results for the fourth quarter and full year ...
Posted: Feb 13, 2017
ROCKVILLE, Md., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on January 31, 2017 of an eighth patent (number 9,555,004) by the United States Pat...
Posted: Feb 8, 2017
ROCKVILLE, Md., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on January 24, 2017 of a seventh patent (number 9,549,940) by the United States Pat...
Posted: Jan 30, 2017
ROCKVILLE, Md., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company (Company) focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that it filed with the Securities and Exchange Commission (SEC) its Quarterly Report o...
Posted: Jan 23, 2017
ROCKVILLE, Md., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company and host invest...
Posted: Jan 3, 2017
ROCKVILLE, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the New Jersey District Court's ...
Posted: Dec 12, 2016
ROCKVILLE, Md., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported that, on November 14, 2016, it received a letter from the Nasdaq Listing Qualifications Dep...
Posted: Nov 17, 2016
FirstPrevious
2
...
NextLast
= add release to Briefcase